Under pressure over its pricing of insulin, Eli Lilly (LLY) on Sunday issued a report in which it claims that the price it was paid for a key diabetes treatment fell by 8.1 percent over the past five years, after subtracting rebates and other discounts.

Specifically, the net price for Humalog, after accounting for those givebacks, was $135 a patient per month last year, down from $147 in 2014. Meanwhile, the average list — or wholesale — price during that same period increased 51.9 percent to $594 per patient each month.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I’d like to know instead what they made per patient in 2005 or even better in 2001 (before the Medicare drug benefit was passed).

    Even if it is the fact (which we can’t confirm) that it’s slightly less per patient per month than in 2014, I’ll bet it’s way higher than in the past and for a very cheap drug in terms of making it.

    They so feel they have a right to make more on every patient every year on every drug that they think this vindicates them!!

    And, as Adam Fein points out, since many uninsured patients DO pay much more it doesn’t address what this does TO patients and their health.

  • Perfect illustration of the gross-to-net bubble. Too many patients pay full price for essential drugs that are sold to insurers and PBMs at deep discounts.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy